[go: up one dir, main page]

MX2011005090A - Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina. - Google Patents

Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina.

Info

Publication number
MX2011005090A
MX2011005090A MX2011005090A MX2011005090A MX2011005090A MX 2011005090 A MX2011005090 A MX 2011005090A MX 2011005090 A MX2011005090 A MX 2011005090A MX 2011005090 A MX2011005090 A MX 2011005090A MX 2011005090 A MX2011005090 A MX 2011005090A
Authority
MX
Mexico
Prior art keywords
phenyl
fluorophenoxymethyl
piperidi
compound
crystalline form
Prior art date
Application number
MX2011005090A
Other languages
English (en)
Inventor
Miroslav Rapta
Robert Chao
Lori Jean Patterson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011005090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2011005090A publication Critical patent/MX2011005090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)

Abstract

La invención provee una sal clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina. Esta invención también provee composiciones farmacéuticas que comprenden la sal cristalina, procesos e intermediarios para preparar la sal cristalina, y métodos para usar la sal cristalina para tratar enfermedades.
MX2011005090A 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina. MX2011005090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
PCT/US2009/064306 WO2010056939A1 (en) 2008-11-14 2009-11-13 Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Publications (1)

Publication Number Publication Date
MX2011005090A true MX2011005090A (es) 2011-09-06

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2011005090A MX2011005090A (es) 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina.
MX2011005088A MX2011005088A (es) 2008-11-14 2009-11-13 Proceso para preparar compuestos de 4-[2-(2-fluorofenoximetil)feni l]piperidina.
MX2011005089A MX2011005089A (es) 2008-11-14 2009-11-13 Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2011005088A MX2011005088A (es) 2008-11-14 2009-11-13 Proceso para preparar compuestos de 4-[2-(2-fluorofenoximetil)feni l]piperidina.
MX2011005089A MX2011005089A (es) 2008-11-14 2009-11-13 Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.

Country Status (28)

Country Link
US (23) US8304433B2 (es)
EP (3) EP2358674B1 (es)
JP (6) JP5529150B2 (es)
KR (3) KR101656339B1 (es)
CN (3) CN102216271B (es)
AR (3) AR074128A1 (es)
AU (3) AU2009313948B2 (es)
BR (3) BRPI0921596B1 (es)
CA (3) CA2739992C (es)
CL (2) CL2011001088A1 (es)
CO (2) CO6361988A2 (es)
CY (3) CY1113622T1 (es)
DK (3) DK2358674T3 (es)
ES (3) ES2401224T3 (es)
HR (3) HRP20120920T1 (es)
IL (2) IL212230A (es)
MX (3) MX2011005090A (es)
MY (2) MY151229A (es)
NZ (2) NZ592543A (es)
PL (3) PL2358676T3 (es)
PT (3) PT2358676E (es)
RU (2) RU2503662C2 (es)
SG (1) SG171311A1 (es)
SI (3) SI2358676T1 (es)
SM (3) SMT201200063B (es)
TW (3) TWI461407B (es)
WO (3) WO2010056938A1 (es)
ZA (1) ZA201103495B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120920T1 (hr) 2008-11-14 2013-01-31 Theravance, Inc. Spojevi 4-[2-(2 fluorofenoksimetil)fenil]piperidina
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
MX2012012245A (es) 2010-04-22 2012-12-17 Theravance Inc Combinacion de una reabsorcion de inhibidor de serotonina y norepirefrina y un agonista opioide para el tratamiento del dolor.
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
CN109640989A (zh) * 2016-08-30 2019-04-16 施万生物制药研发Ip有限责任公司 用于治疗神经性起立性低血压的化合物
WO2019232010A1 (en) 2018-06-01 2019-12-05 Theravance Biopharma R&D Ip, Llc PROCESS FOR PREPARING 2-(1-(tert-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID
WO2023192290A1 (en) 2022-03-28 2023-10-05 Theravance Biopharma R&D Ip, Llc Ampreloxetine for use for treating multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
WO2000002859A1 (en) * 1998-07-10 2000-01-20 Astrazeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
CA2363274A1 (en) * 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60324685D1 (de) * 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
KR20050119682A (ko) * 2003-04-04 2005-12-21 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체
JP2006522027A (ja) * 2003-04-04 2006-09-28 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルオキシフェニル）−ピペリジンまたは−１，２，３，６−テトラヒドロピリジン誘導体
SI1638933T1 (sl) * 2003-06-17 2008-10-31 Pfizer Derivati N-pirolidin-3-il-amida kot inhibitorji ponovnega privzema serotonina in noradrenalina
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
US20070105870A1 (en) 2004-01-13 2007-05-10 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
KR100943555B1 (ko) * 2004-04-30 2010-02-22 워너-램버트 캄파니 엘엘씨 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
JP2010501542A (ja) 2006-08-23 2010-01-21 ファイザー・プロダクツ・インク ピペリジン誘導体
US20090253744A1 (en) * 2006-09-27 2009-10-08 Bakshi Raman K Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
US20110294836A1 (en) 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
TWI438190B (zh) 2008-07-24 2014-05-21 Theravance Inc ３－（苯氧基苯基甲基）吡咯啶化合物
HRP20120920T1 (hr) 2008-11-14 2013-01-31 Theravance, Inc. Spojevi 4-[2-(2 fluorofenoksimetil)fenil]piperidina
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
CN109640989A (zh) * 2016-08-30 2019-04-16 施万生物制药研发Ip有限责任公司 用于治疗神经性起立性低血压的化合物

Also Published As

Publication number Publication date
US20190142816A1 (en) 2019-05-16
CN102209712A (zh) 2011-10-05
US10946006B2 (en) 2021-03-16
CL2011001088A1 (es) 2011-10-14
SMT201300033B (it) 2013-05-06
US10946007B2 (en) 2021-03-16
TW201022206A (en) 2010-06-16
US8304433B2 (en) 2012-11-06
US20200316048A1 (en) 2020-10-08
US20140045892A1 (en) 2014-02-13
MX2011005088A (es) 2011-06-01
US20130030020A1 (en) 2013-01-31
KR20110082196A (ko) 2011-07-18
SMT201200063B (it) 2013-01-14
SI2358676T1 (sl) 2013-01-31
KR101656338B1 (ko) 2016-09-09
ES2401224T3 (es) 2013-04-17
US10576073B2 (en) 2020-03-03
AU2009313951A1 (en) 2010-05-20
JP5598798B2 (ja) 2014-10-01
CO6361993A2 (es) 2012-01-20
NZ592543A (en) 2013-02-22
EP2358676A1 (en) 2011-08-24
US20180050024A1 (en) 2018-02-22
US10034870B2 (en) 2018-07-31
AU2009313948A1 (en) 2010-05-20
RU2503662C2 (ru) 2014-01-10
CA2739992C (en) 2016-09-20
US12239638B2 (en) 2025-03-04
ES2396583T3 (es) 2013-02-22
US20180289687A1 (en) 2018-10-11
CY1113622T1 (el) 2016-06-22
US20100125141A1 (en) 2010-05-20
CN102216271B (zh) 2013-09-25
CN102216271A (zh) 2011-10-12
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
ZA201103495B (en) 2012-01-25
CY1113855T1 (el) 2016-07-27
US9675599B2 (en) 2017-06-13
JP2014139209A (ja) 2014-07-31
PL2358674T3 (pl) 2013-06-28
US8592596B2 (en) 2013-11-26
EP2358676B1 (en) 2012-10-10
US20130030185A1 (en) 2013-01-31
KR101656339B1 (ko) 2016-09-09
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
SI2358675T1 (sl) 2013-01-31
SI2358674T1 (sl) 2013-04-30
US20200000792A1 (en) 2020-01-02
US20200316047A1 (en) 2020-10-08
US10226454B2 (en) 2019-03-12
RU2011123875A (ru) 2012-12-20
DK2358676T3 (da) 2013-01-14
AR074350A1 (es) 2011-01-12
JP2012508759A (ja) 2012-04-12
HK1160449A1 (en) 2012-08-17
JP5529150B2 (ja) 2014-06-25
CY1113623T1 (el) 2016-06-22
EP2358675B9 (en) 2019-09-11
US11596624B2 (en) 2023-03-07
SMT201200065B (it) 2013-03-08
JP2012508761A (ja) 2012-04-12
US8604058B2 (en) 2013-12-10
BRPI0921593B8 (pt) 2021-05-25
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
US20160022660A1 (en) 2016-01-28
RU2515612C2 (ru) 2014-05-20
PT2358674E (pt) 2013-03-05
BRPI0921595B1 (pt) 2020-10-13
JP5506813B2 (ja) 2014-05-28
AU2009313948B2 (en) 2015-03-12
TWI443087B (zh) 2014-07-01
TW201024263A (en) 2010-07-01
BRPI0921596B1 (pt) 2021-10-26
AR114965A2 (es) 2020-11-11
HK1160448A1 (en) 2012-08-17
CA2742105A1 (en) 2010-05-20
CA2742114C (en) 2016-09-13
US20100125092A1 (en) 2010-05-20
CA2742105C (en) 2016-09-13
HK1160452A1 (en) 2012-08-17
MY151211A (en) 2014-04-30
BRPI0921595B8 (pt) 2021-05-25
US9187423B2 (en) 2015-11-17
EP2358675B1 (en) 2012-10-03
AU2009313949B2 (en) 2015-03-19
MY151229A (en) 2014-04-30
BRPI0921593B1 (pt) 2021-05-04
JP2012508760A (ja) 2012-04-12
US9073859B2 (en) 2015-07-07
AU2009313951B2 (en) 2015-03-12
AU2009313949A1 (en) 2010-05-20
EP2358674A1 (en) 2011-08-24
DK2358674T3 (da) 2013-04-08
US10206913B2 (en) 2019-02-19
PL2358675T3 (pl) 2013-03-29
WO2010056939A1 (en) 2010-05-20
BRPI0921596A2 (pt) 2018-03-20
ES2397247T3 (es) 2013-03-05
US20230201181A1 (en) 2023-06-29
JP2014098033A (ja) 2014-05-29
CO6361988A2 (es) 2012-01-20
CN102209712B (zh) 2016-04-06
US11723900B2 (en) 2023-08-15
PL2358676T3 (pl) 2013-03-29
US8247433B2 (en) 2012-08-21
IL212452A0 (en) 2011-06-30
CL2011001093A1 (es) 2011-09-02
IL212230A (en) 2014-12-31
TWI441810B (zh) 2014-06-21
CA2742114A1 (en) 2010-05-20
KR101685186B1 (ko) 2016-12-09
US10441579B2 (en) 2019-10-15
US20140057944A1 (en) 2014-02-27
MX2011005089A (es) 2011-07-29
PT2358676E (pt) 2012-12-06
US9162982B2 (en) 2015-10-20
CN102216272B (zh) 2014-02-05
KR20110082197A (ko) 2011-07-18
AR074128A1 (es) 2010-12-22
CA2739992A1 (en) 2010-05-20
HRP20130300T1 (hr) 2013-04-30
US20160184288A1 (en) 2016-06-30
US20240316024A1 (en) 2024-09-26
HRP20120897T1 (hr) 2012-12-31
DK2358675T3 (da) 2013-01-14
BRPI0921593A2 (pt) 2015-08-18
CN102216272A (zh) 2011-10-12
US20210290608A1 (en) 2021-09-23
KR20110082085A (ko) 2011-07-15
TW201024264A (en) 2010-07-01
HRP20120920T1 (hr) 2013-01-31
EP2358674B1 (en) 2013-01-02
EP2358675A1 (en) 2011-08-24
IL212230A0 (en) 2011-06-30
JP2014101384A (ja) 2014-06-05
PT2358675E (pt) 2012-12-12
WO2010056941A1 (en) 2010-05-20
US20120277438A1 (en) 2012-11-01
US20180055830A1 (en) 2018-03-01
TWI461407B (zh) 2014-11-21
US20140323735A1 (en) 2014-10-30
US20190134019A1 (en) 2019-05-09
US10722504B2 (en) 2020-07-28
RU2011123890A (ru) 2012-12-20
US20100125093A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
MX2011005090A (es) Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina.
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
IN2014KN00948A (es)
TN2012000129A1 (en) SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
TW201144305A (en) Fungicidal oximes and hydrazones
EA201491079A1 (ru) Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
NO20090250L (no) Krystallinske former av 4-[2-(4-metylfenylsulfanyl)-fenyl]piperidin med kombinert serotonin- og norepinefrin reopptaksinhibering for behandlingen av nevropatisk smerte
IN2012DN03391A (es)
MY160392A (en) Triptolide prodrugs
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
TW200420541A (en) Crystalline forms
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
MX2012007223A (es) Carboxamidas fungicidas 2-(ariloxi biciclicas).
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
NO20076396L (no) Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette
EA201000613A1 (ru) Тризамещенные пиперидины
PH12013500051A1 (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
TNSN08461A1 (en) Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.
WO2013026866A3 (en) Pyridine-, pyrazine-, triazine- and tetrazine-derived microbiocides
MX2010002895A (es) Formas polimorficas de (s)-2-((4-benzofuranil)carbonilaminometil)- 1-((4-(2-metil-5-(4-fluorofenil))tiazolil)carbonil)piperidina.

Legal Events

Date Code Title Description
FG Grant or registration